Skip to main content

Table 5 Test characteristics at different faecal haemoglobin concentration by sex and age group

From: Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?

  Positive predictive valuea [%(95% CI)]
Cut-off μg Hb/g faeces Women <55 years Men <55 years p value Women 55–60 years Men 55–60 years p value Women 60–65 years Men 60–65 years p value Women >65 years Men >65 years p value
20 30.6 (28.5–32.7) 44.0 (42.0–45.9) < 0.0001 34.2 (32.0–36.4) 51.9 (50.1–53.8) < 0.0001 32.0 (30.0–34.0) 56.4 (54.7–58.0) < 0.0001 35.2 (33.0–37.3) 57.4 (55.6–59.2) < 0.0001
25 34.5 (32.1–36.9) 47.7 (45.5–49.9) < 0.0001 38.2 (35.6–40.7) 55.2 (50.1–53.8) < 0.0001 34.6 (32.3–36.9) 59.5 (57.7–61.3) < 0.0001 38.9 (36.5–41.4) 60.2 (58.2–62.1) < 0.0001
30 35.7 (33.1–38.3) 49.1 (46.8–51.4) < 0.0001 40.8 (38.1–43.6) 55.2 (53.1–57.2) < 0.0001 36.3 (33.8–38.8) 60.4 (58.5–62.3) < 0.0001 40.2 (37.6–42.8) 61.7 (59.6–63.7) < 0.0001
35 36.4 (33.7–39.1) 49.9 (47.5–52.2) < 0.0001 41.6 (38.8–44.5) 56.4 (54.3–58.5) < 0.0001 37.8 (35.1–40.4) 52.8 (50.8–54.8) < 0.0001 41.3 (38.5–44.0) 63.3 (61.2–65.4) < 0.0001
40 38.0 (35.1–40.9) 50.9 (48.4–53.4) < 0.0001 42.9 (39.8–45.9) 58.0 (55.8–60.2) < 0.0001 38.8 (36.1–41.6) 62.7 (60.7–64.7) < 0.0001 42.8 (40.0–45.7) 64.3 (62.1–66.5) < 0.0001
50 39.9 (36.8–43.0) 52.5 (49.9–55.2) < 0.0001 43.6 (40.4–46.8) 60.9 (58.5–63.4) < 0.0001 42.0 (39.0–45.0) 64.2 (62.1–66.3) < 0.0001 44.4 (41.3–47.5) 66.0 (63.7–68.3) < 0.0001
60 40.8 (37.5–44.2) 54.2 (51.4–57.0) < 0.0001 45.1 (41.7–48.6) 62.3 (59.8–64.9) < 0.0001 42.3 (39.1–45.5) 65.6 (63.4–67.8) < 0.0001 45.4 (42.1–48.7) 67.3 (64.9–69.7) < 0.0001
Positivity rate [%(95% CI)]
 20 3.9 (3.8–4.1) 6.1 (5.9–6.3) < 0.0001 4.4 (4.2–4.6) 7.9 (7.7–8.2) < 0.0001 5.3 (5.1–5.5) 9.5 (9.2–9.8) < 0.0001 6.2 (6.0–6.5) 10.7 (10.3–11.0) < 0.0001
 25 3.1 (3.0–3.3) 5.0 (4.8–5.2) < 0.0001 3.4 (3.3–3.6) 6.6 (6.4–6.9) < 0.0001 4.1 (4.0–4.3) 8.1 (7.8–8.3) < 0.0001 5.0 (4.8–5.3) 9.0 (8.7–9.4) < 0.0001
 30 2.8 (2.6–2.9) 4.5 (4.3–4.7) < 0.0001 3.0 (2.8–3.2) 6.0 (5.7–6.2) < 0.0001 3.6 (3.0–3.4) 7.3 (7.0–7.5) < 0.0001 4.5 (4.3–4.7) 8.1 (7.8–8.5) < 0.0001
 35 2.5 (2.4–2.6) 4.1 (3.9–4.3) < 0.0001 2.7 (2.6–2.9) 5.4 (5.2–5.7) < 0.0001 3.2 (3.0–3.4) 6.7 (6.5–7.0) < 0.0001 4.1 (3.8–4.3) 7.5 (7.2–7.8) < 0.0001
 40 2.3 (2.1–2.4) 3.7 (3.6–3.9) < 0.0001 2.5 (2.3–2.6) 5.0 (4.8–5.3) < 0.0001 2.9 (2.8–3.1) 6.2 (6.0–6.5) < 0.0001 3.7 (3.5–4.0) 6.9 (6.6–7.2) < 0.0001
 50 2.0 (1.9–2.1) 3.3 (3.1–3.4) < 0.0001 2.2 (2.1–2.4) 4.4 (4.2–4.6) < 0.0001 2.5 (2.4–2.7) 5.5 (5.2–5.7) < 0.0001 3.3 (3.1–3.5) 6.1 (5.8–6.4) < 0.0001
 60 1.8 (1.6–1.9) 2.9 (2.8–3.1) < 0.0001 2.0 (1.8–2.1) 3.9 (3.7–4.1) < 0.0001 2.3 (2.1–2.4) 5.0 (4.8–5.2) < 0.0001 2.8 (2.7–3.0) 5.5 (5.2–5.8) < 0.0001
Colorectal Cancer (CRC) Detection Rate [‰ (95% CI)]
 20 1.6 (1.2–2.0) 2.2 (1.7–2.6) 0.053 2.1 (1.7–2.6) 4.5 (3.8–5.2) < 0.0001 2.3 (1.8–2.7) 6.4 (5.6–7.3) < 0.0001 3.5 (2.8–4.1) 9.3 (8.1–10.4) < 0.0001
 25 1.5 (1.2–1.9) 2.0 (1.6–2.4) 0.107 2.0 (1.6–2.4) 4.3 (3.6–5.0) < 0.0001 2.1 (1.7–2.6) 6.1 (5.3–6.9) < 0.0001 3.2 (2.6–3.9) 8.7 (7.6–9.8) < 0.0001
 30 1.5 (1.1–1.8) 1.9 (1.5–2.3) 0.127 2.0 (1.5–2.4) 4.1 (3.4–4.8) < 0.0001 2.1 (1.6–2.5) 5.9 (5.1–6.7) < 0.0001 3.0 (2.4–3.6) 8.4 (7.3–9.5) < 0.0001
 35 1.5 (1.1–1.8) 1.9 (1.5–2.3) 0.127 1.9 (1.5–2.3) 4.0 (3.3–4.7) < 0.0001 2.0 (1.6–2.5) 5.8 (5.0–6.6) < 0.0001 2.9 (2.3–3.5) 8.3 (7.2–9.4) < 0.0001
 40 1.4 (1.1–1.8) 1.8 (1.5–2.3) 0.150 1.8 (1.4–2.2) 3.9 (3.3–4.6) < 0.0001 2.0 (1.5–2.4) 5.5 (4.8–6.3) < 0.0001 2.8 (2.2–3.4) 8.0 (7.0–9.1) < 0.0001
 50 1.4 (1.0–1.7) 1.7 (1.3–2.1) 0.241 1.7 (1.3–2.1) 3.7 (3.1–4.4) < 0.0001 1.8 (1.4–2.2) 5.3 (4.5–6.0) < 0.0001 2.6 (2.0–3.2) 7.8 (6.8–8.9) < 0.0001
 60 1.3 (1.0–1.6) 1.6 (1.2–1.9) 0.328 1.7 (1.3–2.0) 3.6 (3.0–4.2) < 0.0001 1.7 (1.3–2.1) 5.0 (4.3–5.8) < 0.0001 2.5 (2.0–3.1) 7.6 (6.5–8.6) < 0.0001
Advanced Neoplasia (AN) Detection Rate [‰ (95% CI)]
 20 12.1 (11.1–13.0) 26.9 (15.3–28.5) < 0.0001 15.0 (13.8–16.2) 41.3 (39.2–43.4) < 0.0001 16.9 (15.6–18.2) 53.6 (51.2–55.9) < 0.0001 21.9 (20.3–23.6) 61.2 (58.3–64.1) < 0.0001
 25 10.8 (9.9–11.8) 23.9 (22.5–25.4) < 0.0001 13.1 (12.0–14.2) 36.5 (34.6–38.5) < 0.0001 14.4 (13.2–15.5) 47.9 (45.7–50.2) < 0.0001 19.6 (18.0–21.2) 54.2 (51.5–56.9) < 0.0001
 30 9.9 (9.0–10.7) 21.9 (20.5–23.3) < 0.0001 12.3 (11.2–13.3) 33.6 (31.7–35.4) < 0.0001 13.0 (11.9–14.1) 44.0 (41.9–46.1) < 0.0001 18.0 (16.5–19.5) 50.1 (47.5–52.8) < 0.0001
 35 9.1 (8.2–9.9) 20.3 (19.0–21.7) < 0.0001 11.4 (10.4–12.4) 31.5 (29.6–33.3) < 0.0001 12.1 (11.1–13.2) 35.6 (33.7–37.5) < 0.0001 16.8 (15.4–18.2) 47.6 (45.0–50.1) < 0.0001
 40 8.6 (7.8–9.4) 19.1 (17.8–20.4) < 0.0001 10.7 (9.7–11.7) 30.0 (28.2–31.8) < 0.0001 11.4 (10.4–12.4) 39.0 (37.0–47.1) < 0.0001 16.0 (14.6–17.5) 44.6 (42.1–47.1) < 0.0001
 50 7.9 (7.1–8.7) 17.2 (15.9–18.4) < 0.0001 9.7 (8.8–10.7) 26.7 (25.1–28.4) < 0.0001 10.7 (9.7–11.7) 35.2 (33.3–37.1) < 0.0001 14.5 (13.1–15.8) 40.4 (38.1–42.8) < 0.0001
 60 7.2 (6.5–8.0) 16.0 (14.8–17.2) < 0.0001 8.9 (8.0–9.8) 24.5 (22.9–26.1) < 0.0001 9.7 (8.7–10.7) 32.8 (30.9–34.7) < 0.0001 12.9 (11.7–14.2) 37.1 (34.9–39.4) < 0.0001
  1. aPPV applies for AN: defined as advanced adenoma (AA) plus colorectal cancer (CRC). Advanced adenomas: adenomas ≥10 mm, ≥3 adenoma, adenoma with a villous component (i.e., tubulovillous or villous adenoma) or adenomas with severe/high-grade dysplasia